MEDPAGE TODAY– Feb. 20, 2014 – In a trial of 452 patients
with advanced cervical cancer that has recurred or did not respond to initial
therapy, the women given Avastin in addition to combination chemotherapy survived
an average of 17 months. That compared to 13.3 months for women treated with
the combination chemotherapy alone. The study was published in the Feb. 20 New England Journal of Medicine.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment